Previous Article | Next Article 
Molecular and Cellular Biology, February 2001, p. 781-793, Vol. 21, No. 3
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.3.781-793.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Glucocorticoid Receptor Homodimers and
Glucocorticoid-Mineralocorticoid Receptor Heterodimers Form in the
Cytoplasm through Alternative Dimerization Interfaces
Joanne G. A.
Savory,1
Gratien G.
Préfontaine,1
Claudia
Lamprecht,2
Mingmin
Liao,2
Rhian F.
Walther,1
Yvonne A.
Lefebvre,2,3,* and
Robert J. G.
Haché2,3
Departments of
Medicine2 and Biochemistry, Microbiology
& Immunology3 and Graduate Program in
Biochemistry,1 The Loeb Health Research
Institute at the Ottawa Hospital, University of Ottawa, Ottawa,
Ontario, Canada K1Y 4E9
Received 29 June 2000/Returned for modification 10 August
2000/Accepted 6 November 2000
 |
ABSTRACT |
Steroid hormone receptors act to regulate specific gene
transcription primarily as steroid-specific dimers bound to palindromic DNA response elements. DNA-dependent dimerization contacts mediated between the receptor DNA binding domains stabilize DNA binding. Additionally, some steroid receptors dimerize prior to their arrival on
DNA through interactions mediated through the receptor ligand binding
domain. In this report, we describe the steroid-induced homomeric
interaction of the rat glucocorticoid receptor (GR) in solution in
vivo. Our results demonstrate that GR interacts in solution at least as
a dimer, and we have delimited this interaction to a novel interface
within the hinge region of GR that appears to be both necessary and
sufficient for direct binding. Strikingly, we also demonstrate an
interaction between GR and the mineralocorticoid receptor in solution
in vivo that is dependent on the ligand binding domain of GR alone and
is separable from homodimerization of the glucocorticoid receptor.
These results indicate that functional interactions between the
glucocorticoid and mineralocorticoid receptors in activating specific
gene transcription are probably more complex than has been previously appreciated.
 |
INTRODUCTION |
The effects of corticosteroids are
determined through asymmetric distribution of the mineralocorticoid and
glucocorticoid nuclear hormone receptors (MR and GR) and the protective
effects of 11
-hydroxysteroid dehydrogenase, which selectively
metabolizes glucocorticoids (2, 20, 31). MR is highly
sensitive to both mineralocorticoids and glucocorticoids, while GR
responds only to higher levels of glucocorticoids and is mostly
insensitive to mineralocorticoids.
Coordinate signaling by GR and MR is specifically relevant to tissues
such as the brain, where an abundance of MR and GR in areas such as the
hippocampus is accompanied by an absence of 11
-hydroxysteroid
dehydrogenase (14). Indeed, the effects of GR and MR are
critical for homeostatic control of CAl pyramidal neurons, where the
two receptors differentially mediate the control of ion regulation and
transmitter responsiveness (27). Thus, MR and GR signaling
influence memory, mood, and neuronal survival. Elevated cortisol levels
correlate with depression and other stress-related psychopathologies
and with a long-term attenuation of serotonin signaling (28, 29,
61).
GR and MR function predominantly to regulate specific gene expression
patterns through palindromic response elements that accommodate
receptor dimers (1). The DNA binding domains (DBDs) of the
steroid hormone receptors are highly conserved. As a result, GR and MR,
as well as progesterone receptors (PR) and androgen receptor (AR), bind
in closely related ways to broadly overlapping response elements.
Homodimerization contacts mediated through the receptor DBDs occur on
DNA binding and are mediated through specific contacts involving
residues in the second zinc finger of the receptor DBDs
(38).
The potential for transcriptional regulation via heteromeric complexes
of these steroid receptors has recently been substantiated by reports
that GR and MR can function as DNA-bound heterodimers to modulate
transcription in ways that are distinct from the GR and MR homodimers
(37, 60). In vitro experiments have demonstrated the
potential of GR and MR to form heterodimers on palindrominc response
elements, while regulatory experiments have demonstrated that composite
transcriptional responses are possible on costimulation of MR and GR in
the cells. Another report has since demonstrated a similar potential
for GR to regulate transcription as a DNA-bound heterodimer with AR
(6).
For the majority of nuclear hormone receptors, however, the
possibilities for DNA-dependent dimerization (39) may be
restricted by additional dimerization contacts that form in solution
between the receptor ligand binding domains (LBDs) (42).
Thus, retinoid, thryoid, vitamin D, and orphan nuclear receptors act
primarily as heterocomplexes with retinoic acid X receptors (RXRs) but
can also form homodimers in solution under certain conditions
(39). For example, the binding of
3,5,3'-L-triiodothyronine to thyroid hormone receptor (TR)
destabilizes TR homodimers in favor of TR-RXR heterodimers, while the
binding of 9-cis-retinoic acid to RXR decreases
heterodimerization with TR in favor of RXR homodimers (35).
Dimerization of steroid hormone receptors in solution prior to DNA
binding also has been described. However, the proclivity of these
receptors for heterodimerization is considerably less and seems to
encourage their functioning as steroid-specific dimers. The
and
estrogen receptors (ERs) form homo- and heterodimers in solution
through a motif in the LBD and make subsequent DNA-dependent contacts
within their zinc fingers on DNA binding. Similarly, the PR A and B
isoforms homo-and heterodimerize in solution and on DNA binding.
For ER
, biochemical and crystallographic studies have demonstrated
that solution dimerization occurs through a motif at the C-terminal
region of the LBD anchored by
-helix 10 but also involving helices
7, 8 and 9 (5, 18). This interface aligns closely with
that observed for solution dimerization of RXR (4). The dimerization interface for PR is also localized to the C terminus of
the receptor LBD but is only about half the size of that for ER
(56, 66). This decrease in surface area is reflected by a
decreased stability of PR LBD dimers in biochemical experiments (15, 66). Additional contacts that have been reported to
occur between the hinge region of PR (59) may act to
stabilize PR dimers. In addition, individual domains within PR, AR, and
ER
appear to be able to form intramolecular contacts (30, 32, 58).
The ability of GR to form homodimers in solution has been debated
extensively without resolution, while the prospects for MR
homodimerization and GR-MR heterodimerization prior to DNA contact have
not been considered. Initial biochemical studies indicated that
liganded GR migrated in sucrose gradients at 4S in a monomeric form
(36). More careful preparations or the inclusion of
cross-linking agents revealed the presence of a 6S form with enhanced
DNA binding activity that was suggested to reflect the presence of GR
homodimers in solution (67). However, the results of
studies measuring the DNA binding of wild-type (WT) GR and GR peptides
under a variety of experimental conditions have alternatively supported
the cooperative binding of GR monomers or the coordinate binding of
preformed GR dimers (10-12, 17, 43, 54, 62, 63).
Since the ability of GR and MR to form homo- and heterodimers in
solution prior to their arrival on hormone response elements may be a
determining factor for the coordination of corticosteroid signaling
through GR and MR, we have undertaken a directed analysis of the
ability of GR to form homomeric complexes in solution and to
heterodimerize with MR in the cell. Our results demonstrate that
steroid treatment induces the association of GR in solution into at
least a receptor dimer, through an interface within a 35-amino-acid
region of the receptor hinge that is not featured in this way in the
dimerization of other nuclear receptors. The occurrence of this
interaction in vivo is demonstrated in nuclear cotransport experiments
in which the nuclear accumulation GR mutants deficient in nuclear
localization is shown to be dependent on this short region of the GR
hinge. Using the same assay, we have also determined that GR can enter
into a heteromeric interaction in solution with MR through determinants
in the GR LBD that are separable from the amino acids required for the
homomeric interaction of GR in solution. These results suggest the
potential for higher-order corticosteroid receptor complexes in the cell.
 |
MATERIALS AND METHODS |
Plasmids.
The compositions of the GR and MR peptides
employed are summarized in the figures. Many of the plasmids used have
been described previously (19, 22, 47, 51, 52). All other
plasmids were constructed by standard restriction enzyme cloning or
through PCR amplification of the inserts. Reading frame reconstruction and mutations were verified by DNA sequencing. All plasmids constructed for in vitro translation were either in a pGEM-7Z backbone (Promega) or
a pTL2 backbone (44). Plasmids expressing glutathione
S-transferase fusion proteins were constructed in a pGEX-3X
or pGEX-2T (Pharmacia) backbone. Yeast expression plasmids were
constructed in pGAD and pAS2 backgrounds (Clontech). The c-myc epitope
tag employed in many experiments has been utilized previously (3,
46). MR with a BuGR2 (buGR) epitope tag (buMR) was
constructed by insertion of the BuGR antibody epitope of amino acids
407 to 423 from rat GR at the N terminus of the rat MR expression
plasmid pTL2MR, which was derived from p6RMR. The pKA epitope has been
utilized previously (65).
Mammalian culture.
Sf7 cells stably transfected to express
myGR (46) were maintained in Dulbecco's modified Eagle's
medium (DMEM) supplemented with 10% 10% FBS in the presence of 50 µg of G418 per ml. The parental cell line was grown in DMEM-10% FBS
in the absence of G418. COS7 cells were maintained in DMEM-10% FBS.
Transient transfections were performed using Lipofectamine (10 µl per
60-mm dish) (GIBCO BRL) and an 8-h incubation time as previously
described (51). Transfected cells were maintained for 16 h
in complete serum and were withdrawn from serum for 21 h prior to
treatment. Hormone treatments with 10
6 M dexamethasone
(Dex) or cortisol were carried out for 1 h.
In vitro protein binding assays.
The detailed protocol for
the immunoprecipitation binding assay for GR-interacting proteins has
been described in detail previously (46). Whole-cell
extracts for immunoprecipitation binding assays were prepared from Sf7
cells stably expressing myGR, or the control parental cell line, by
sonication in TEGD buffer (10 mM Tris-HCl [pH 7.4], 1 mM EDTA, 10%
glycerol, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride)
followed by centrifugation for 5 min at 16,000 × g. To
dissociate the heat shock protein complex after steroid binding, extracts were incubated with 10
6 M Dex for 2 h at
4°C and then for 30 min at 25°C. Salt-induced hsp release was
accomplished separately by incubation of the extracts in (0.4 M) NaCl
for 2 h at 4°C. In experiments where the GR-hsp interaction was
maintained through the binding assay, the GR-chaperone complex was
stabilized by the addition of Na2MoO4 to 20 mM
in all buffers. To prepare the immunoprecipitates, the
molybdate-stabilized and the Dex-treated extracts were diluted
threefold with binding buffer (25 mM HEPES [pH 7.9], 60 mM KCl, 0.5 mM EDTA, 12% glycerol, 0.1% NP-40, 0.2 mM dithiothreitol, 0.2 mM
phenylmethylsulfonyl fluoride) in the presence and absence of 20 mM
Na2MoO4 respectively, while the salt-treated
extracts were diluted with binding buffer without KCl to a final salt
concentration of 60 mM. Immunoprecipitations for myGR and control Sf7
extracts were performed with the anti-myc antibody, 9E10, as described
previously (46) and included at least three washes with
binding buffer. Receptor concentrations used in subsequent binding
assays were verified by quantitative Western blotting using a Bio-Rad
GS525 molecular imager with a CH screen.
In vitro-translated, 35S-labeled GR peptides were prepared
in rabbit reticulocyte lysate (Promega) using
[35S]methionine (1 mCi/mmol; Amersham/Pharmacia). Dex and
salt treatments and Na2MoO4 stabilization were
performed exactly as described for the whole-cell extracts. hsp
dissociation following Dex and NaCl treatments was confirmed by sucrose
gradient centrifugation analysis. In vitro-translated GRs were
quantified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and molecular imager analysis
The 9E10 immunoprecipates were prepared for binding to in
vitro-translated GRs by preincubation with unprogrammed reticulocyte lysate (10% solution in binding buffer with
Na2MoO4 as required) at 4°C for 2 h
followed by incubation with the 35S-labeled in
vitro-translated proteins in binding buffer in the presence or absence
of Na2MoO4 as required. Specific binding was revealed by three subsequent washes with 500 µl of ice-cold binding buffer and SDS-PAGE and molecular imager analysis of the bound proteins.
GST-GR fusion proteins were prepared as previously described (46,
51), with yields and purity determined by scans of Coomassie blue-stained SDS-PAGE gels. Binding reactions with
35S-labeled, in vitro-translated GRs were performed, and
the products were analyzed by exactly the same protocol used for the
immunoprecipitation binding reactions.
For direct binding studies, purified GST-GRX550 (GR amino
acids 407 to 550) with a C-terminal extension (LARRASYP) containing a
protein kinase A phosphorylation site was labeled with 32P
using protein kinase A to a specific activity of 2.3 × 107 dpm/mg. The 32P-labeled GRX550
moiety was released from the GST purification tag by thrombin cleavage
and recovered, and binding to GST GRs was performed by the same method
as the immunoprecipition binding assays.
Cross-linking of GR and FTZ-F1 peptides was performed by the protocol
described previously to study the multimerization of p53
(55). The GR505-550 (amino acids 505 to 550)
and Drosophila FTZ-F1 peptides (amino acids 575 to 620, exactly analogous to GR amino acids 505 to 550) were expressed as GST
fusion proteins with the C-terminal protein kinase A motif, labeled,
cleaved from the GST, and purified as for GST-GRX550. Equal
counts of each peptide were incubated in 200 mM
Na3PO4 (pH 7.4) buffer at 4°C for 30 min in
the presence of increasing concentrations of glutaraldehyde. The
cross-linked peptides were resolved by Tris-Tricine SDS-16.5% PAGE
(Bio-Rad) and visualized by autoradiography.
Yeast two-hybrid Assays.
The yeast strain Y190 was grown in
yeast extract-peptone-dextrose (YEPD). Transformation was carried out
using the lithium acetate method with plasmid DNA (53).
Yeast colonies transformed with fusion constructs were grown in
synthetic media lacking either leucine or tryptophan or both.
Transformed yeast were selected and cultured overnight in the absence
of hormone. The yeast cultures were then subcultured (1:10) in fresh
selective media that contained either ethanol or 10
6 M
desacetylcortivazol (DAC) (22) and grown for a further
16 h. The optical density at 600 nm (OD600) was
determined, and the cultures were then assayed for
-galactosidase activity.
-Galactosidase assays were performed as described elsewhere
(52).
-Galactosidase units were calculated using the
equation (1,000 OD420)/(t × v × OD600), where t is the
reaction time at 30°C (in minutes) and v is the initial
volume of culture used (in milliliters) (52).
Indirect and direct immunofluorescence.
GR and MR expression
vectors were expressed from recombinant plasmids in COS7 cells by
Lipofectamine-mediated transfection singly or in combination. Relative
levels of expression were determined by Western blotting of whole-cell
extracts using the BuGR2 antibody that recognized all of
the constructs used in this study. For cotransport assays, a minimum
4:1 ratio of transporting receptor to passenger was confirmed prior to
immunofluorescence. The amounts of plasmid transfected varied from 60 to 2,500 ng. To monitor the subcellular distribution by indirect
immunofluorescence, transfected cells were plated onto
poly-L-lysine-coated glass coverslips 24 h following
transfection and incubated for a further 8 h in DMEM containing
10% charcoal-stripped fetal calf serum. The cells were synchronized to
G0 by incubation in serum-free DMEM for a further 21 h
prior to the initiation of treatment. Vehicle, Dex, or cortisol was
added to a final concentration of 10
6 M in serum-free
medium for 1 h prior to fixation of the cells. Indirect
immunofluorescence was carried out exactly as described previously
(48, 51, 68), with either primary anti-GR antibody BuGR2 (Affinity BioReagents, Inc.) for detection of WT GR
and buMR or the anti-myc antibody, 9E10, for detection of myc
epitope-tagged GR derivatives. In most experiments,
fluorescein-conjugated anti-mouse sheep immunoglobulin (Boehringer
Mannheim) was the secondary antibody used. However, to detect 9E10
signals in the presence of green fluorescent protein (GFP) we employed
a rhodamine red-conjugated donkey anti-mouse secondary antibody
(Jackson ImmunoResearch laboratories). Slides were examined for
subcellular localization of GRs on a Zeiss Axioskop microscope, and the
images were captured using Northern Eclipse 5 software (Empix Imaging
Inc.). Cells were classified into one of five categories ranging from
exclusively nuclear (N) to exclusively cytoplasmic (C) by visual
observation, as we and others have previously established (48,
51, 68). Quantification was performed using double-blind
encryption. All experiments were repeated in triplicate in at least
three independent trials. Visualization of
GFP-GRN524NL1
expressed alone and in
combination with full-length GR and MR constructs was performed by
direct fluorescence observation of live cells and quantified as for
indirect immunofluorescence.
 |
RESULTS |
Oligomerization of GR in solution in vitro is dependent on the
receptor hinge.
To begin to assess the potential for
steroid-activated GRs to oligomerize in the absence of DNA, we tested
the ability of in vitro-translated WT rat GR to bind to GR
immunoprecipitated from whole-cell extracts of Dex-treated murine Sf7
fibroblasts (Fig. 1). An N-terminal c-myc
epitope tag on GR stably expressed in Sf7 cells allowed for selective
discrimination of the cellular receptor from the in vitro-translated GR
peptides. Previously, we had shown that this assay accurately mapped a
protein-protein interaction between GR and octamer transcription
factors 1 and 2 that leads to the recruitment of the octamer factors to
the mouse mammary tumor virus promoter in tissue culture cells
(46).

View larger version (47K):
[in this window]
[in a new window]
|
FIG. 1.
Binding of in vitro-translated, 35S-labeled
GR to myGR immunoprecipitated from whole-cell extracts is dependent on
hsp dissociation. (A) Immunoprecipitates with myc epitope antibody 9E10
from whole-cell extracts prepared from Sf7 cells expressing myGR (lanes
4 to 6) or control cells lacking GR (lanes 7 to 9) were tested for
binding to in vitro-translated firefly luciferase (Luc.) or WT GR. Both
the cells and in vitro-translated receptors were treated with
10 6 M Dex, as indicated in the figure and described in
detail in Materials and Methods. For binding reactions performed in the
absence of steroid, association of GR with the chaperone complex was
stabilized in cell extracts prior to immunoprecipitation and in the
binding assays through the inclusion of 20 mM
Na2MoO4 in all buffers as indicated. Specific
myGR binding (Bound, lanes 4 to 9) was revealed by SDS-PAGE and
fluorography and is compared to 10% of the in vitro-translated
proteins added to the binding-assay mixture (Input, lanes 1 to 3).
Loading of the GR immunoprecipitates with or without hormone is
revealed by Western blotting in lanes 10 and 11. (B) 9E10
immunoprecipitates from Sf7 and Sf7 (GR+) cells were tested
for binding to in vitro-translated GR. In lanes 1 to 3, the cells and
in vitro-translated receptors were treated with 10 6 M
Dex, while in lanes 4 to 6, the immunoprecipitates and in
vitro-translated GRs were treated with 0.4 M NaCl to strip the
hsp-immunophilin complex from the receptor prior to binding. Binding of
in vitro-translated GR is compared to 10% of the input from the in
vitro translation. Loading of the GR immunoprecipitates in the binding
assay is revealed by Western blot analysis in lanes 7 and 8.
|
|
In vitro-translated, Dex-treated GR was observed to bind efficiently to
immunoprecipitated myGR (Fig. 1A, lane 6) but was not retained by
immunoprecipitates prepared from the parental cell line lacking myGR
(lane 9). Binding occurred independently of added DNA and was fully
resistant to treatment of the binding-reaction mixture with DNase I
(50). We also obtained very similar binding in experiments
employing the antagonist RU486 as the GR ligand, indicating that GR-GR
interaction was unlikely to be influenced significantly by agonist or
antagonist-specific receptor conformations (50).
Prior to exposure to ligand, GR exists in the cytoplasm as a monomer in
a chaperone complex featuring hsp90 and other heat shock proteins and
immunophilins (45). The chaperone complex can be
maintained in vitro through the stabilizing effects of sodium molybdate
(33). Chaperone association appeared to effectively block
GR dimerization in this assay, since no binding of the in vitro-translated GR to myGR was observed for molybdate-stablized receptors (Fig. 1A, lane 5).
To determine whether the GR-GR interaction we observed was strictly
dependent on ligand or merely required the dissociation of GR from the
chaperone complex, we assessed the ability of free GRs to associate in
the absence of steroid (Fig. 1B). In this experiment, the
immunopreciptitated myGR and the in vitro-translated receptor were
dissociated from the hsp-immunophilin complex by treatment with 0.4 M
NaCl at 30°C prior to binding (16). Again, no GR bound
to immunoprecipitates from the parental Sf7 cells (lanes 2 and 5).
However, unliganded GRs, stripped free of hsps, interacted with the
same efficiency as we observed for the Dex-treated receptors (lanes 3 and 6).
To begin to localize the determinants required for solution
oligomerization of GR, we examined the binding of a series of truncated
in vitro-translated GR peptides to the myc-tagged GR expressed in
fibroblasts (Fig. 2). Notably, GR-GR
binding was unaffected by deletion of the receptor LBD as a peptide
encoding amino acids 1 to 556 of GR was retained by myGR with the same efficiency as full-length, liganded receptor (lanes 5 and 6). Truncation of GR to amino acid 523 resulted in a small, but
reproducible decrease in binding (lane 7), suggesting that 523 was
immediately adjacent to or just within the beginning of the binding
interface. Further truncation of the receptor through the hinge region
to amino acid 494 completely abrogated binding (lane 8).

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 2.
Binding of in vitro-translated, 35S-labeled
GR to liganded myGR immunoprecipitated from whole-cell extracts is
dependent on the receptor hinge region. Immunoprecipitates from
whole-cell extracts prepared from Sf7 cells expressing myGR and treated
with 10 6 M Dex for 1 h prior to harvesting [Sf7
(GR+), lanes 5 to 8 and 18 to 22] or control Dex-treated
cells lacking myGR (Sf7, lanes 9 to 12 and 23 to 27) were tested for
binding to in vitro-translated GR derivatives (lanes 5 to 12 and 18 to
27), whose composition is summarized schematically at the top of each
panel. In vitro-translated WT GR and GR peptides X795, 505C, and 547C
were treated with 10 6 M Dex, while GR peptide
X 509-631 was treated with 0.4 M NaCl to strip away the chaperone
complex prior to incubation with liganded, immunoprecipitated myGR.
Dissociation of the in vitro-translated GRs from the hsp complex on Dex
and NaCl treatment was confirmed by sedimentation analysis of the
receptor over 15 to 30% sucrose gradients (Savory et al.,
unpublished). Lanes 1 to 4 and 13 to 17 show 10% of the input from the
in vitro translations.
|
|
Large deletions from the N terminus of GR also had little effect on
binding to myGR until they affected the hinge region. Truncation
through the GR DBD to amino acid 505 left a GR peptide that still bound
to myGR strongly (Fig. 2, lanes 18 to 20). This result conclusively
excluded the possibility that binding might be stabilized by DNA.
Further truncation through the hinge region of the receptor to amino
acid 547 left an LBD peptide that was unable to bind to the myc-tagged
receptor in the presence of Dex (lane 21). These results suggested that
the primary determinants for GR-GR binding in solution reside within
the receptor hinge region between amino acids 505 and 523. The
inability of a GR peptide containing an internal truncation between
amino acids 509 to 631 to bind myGR following NaCl-mediated stripping
of the hsp complex from the GR peptide (lane 22) provided further
evidence supporting the involvement of the hinge region in the GR-GR interaction.
To ensure that our results were not biased by the nature of the assay
employed, we reexamined GR-GR binding in solution in a GST pulldown
experiment (Fig. 3). Four GR peptides
were expressed as GST fusion proteins (Fig. 3A) and tested for their
ability to bind in vitro-translated, liganded, WT GR. The results
obtained (Fig. 3B) closely mirrored those obtained in
immunoprecipitation binding experiments. In vitro-translated GR bound
very strongly to the two GR peptides containing only the hinge region
in common, X568 (amino acids 407 to 568) and 505C (amino acids 505 to
795) (lanes 4 and 5). By contrast, no binding was obtained to the LBD peptide (542C) (lane 6) or to GST alone (lane 2). Lastly, the increased
sensitivity of this assay compared to that of the immunopreciptation experiments allowed for the visualization of a much weaker interaction between the in vitro translated GR and the receptor N terminus (lane
3). However, the significance of this interaction, which was not
confirmed in other assays, remains to be established.

View larger version (40K):
[in this window]
[in a new window]
|
FIG. 3.
Amino acids 505 to 568 are required for GR-GR binding in
a GST pulldown assay. Binding of in vitro-translated,
35S-labeled, Dex-treated, WT GR to GST-GR fusion proteins
(B), whose composition is summarized schematically in the top panel A,
is compared to 10% of the input 35S-labeled GR from the in
vitro translation (lane 1). A Coomassie blue-stained SDS-PAGE gel of
the loading of the GST fusion proteins on the Sepharose beads is shown
in the middle panel.
|
|
The GR hinge is sufficient for direct GR-GR binding in vitro.
To examine whether the association of GR was direct and to determine
whether the GR hinge region might be sufficient for GR-GR binding in
solution, we performed two experiments. In the first, we examined the
ability of a GR construct containing amino acids 407 to 550 (GRX550), expressed in and purified from bacteria, to bind
to GST-GR fusion peptides bound to glutathione-Sepharose (Fig.
4A). To visualize binding, the purified
peptide was 32P labeled using protein kinase A at an
ectopic recognition motif included at its C terminus.

View larger version (48K):
[in this window]
[in a new window]
|
FIG. 4.
Amino acids 505 to 550 are sufficient for GR-GR binding
in vitro. (A) GST-GRX550 containing a protein kinase A
(PKA) recognition site purified free of the GST moiety and labeled with
32P by protein kinase A was tested for binding to GST-GR
fusion proteins. The compositions of all of the proteins used in the
assays are summarized at the top. GRX550 binding is
compared to 10% of the input peptide shown in lane 1 and was resolved
by autoradiography of an SDS-PAGE gel (18% polyacrylamide). (B).
Tricine-Tris PAGE (16.5% polyacrylamide) of 32P-labeled
GR505-550 (lanes 1 to 4) and the analogous peptide from
the monomeric nuclear receptor FTZ-F1 from Drosophila (lanes
5 to 8) following binding reactions performed in increasing
concentrations of the glutaraldehyde cross-linking agent as indicated.
The arrow indicates the position of migration of the cross-linked GR
peptides.
|
|
32P-labeled GRX550 bound efficiently to GST
fusion proteins encoding the X550 and to a shorter GR peptide
containing only amino acids 505 to 550 from the GR hinge region
(GR505-550) (Fig. 4A, lanes 4 and 5). By contrast,
no binding was detected to GST alone or to GST-GR22-437 or
GST-GR542C (lanes 2, 3, and 6).
In a second assay (Fig. 4B), we assessed whether GR505-550
peptide dimers could be directly visualized through addition of a
cross-linking agent. As a control for nonspecific cross-linking, the
analogous peptide from the monomeric Drosophila FTZ-F1
nuclear receptor was tested in parallel with GR505-550. A
band in high-percentage SDS-PAGE gels representative of at least GR
peptide dimers increased in intensity in proportion to the
concentration of the glutaraldehyde cross-linking agent included in the
incubation of 32P-labeled GR505-550 (Fig. 4B,
lanes 1 to 4). Indeed, the interaction observed for the GR peptide in
this experiment is similar to the dimerization observed for a peptide
from the tetramerization domain of p53 in a similar assay
(55). By contrast, in the same experiment, the analogous
FTZ-F1
peptide displayed no association, even at the highest level
of cross-linking agent (lanes 5 to 8). Together, these data provide
strong biochemical evidence implicating the hinge region of GR in a
direct homomeric protein-protein interaction that is required and may
be sufficient for the formation of GR dimers or higher-order oligomers
in solution.
Yeast two-hybrid GR-GR interactions converge at the receptor
hinge.
As a first step toward assessing the involvement of the GR
hinge region in DNA-independent oligomerization of GR within the cell,
we assessed the interaction between GR peptides in a two-hybrid analysis in yeast (Fig. 5). The GR LBD in
the presence or absence of the hinge region
(GR505C/GR540C) and the GR DBD including the hinge region (X556) were expressed as a series of five fusion proteins
with the Gal4 activation domain or the Gal4 DBD. A sixth fusion
protein, with GRX556 fused to the Gal4 DBD was toxic to the
cells and thus could not be tested (34).

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 5.
Amino acids 505 to 556 are required for GR-GR binding in
a yeast two-hybrid assay. Relative activation of a -galactosidase
reporter gene from Gal4 response elements on coexpression of the
indicated Gal-GR fusion proteins, whose composition is summarized at
the top, following treatment of liquid cultures for 16 h with
10 6 M DAC or vehicle. The error bars indicate the
standard errors of the means from three independent experiments
performed in duplicate. All Gal-GR fusion proteins were expressed to
similar levels as determined by Western blot analysis of yeast extracts
(Savory et al., unpublished).
|
|
The GR LBD constructs (GR505C/GR540C) expressed
at low levels in yeast fused to the Gal4 DBD activated transcription
poorly in response to the synthetic steroid DAC. Coexpression of a
second GR540C linked to the Gal activation domain had no
further effect on
-galactosidase activity, confirming that the GR
LBD is not sufficient for dimerization. The lack of interaction between
the GR540C peptides was not due to a lack of responsiveness
to DAC, since the Gal DBD-GR540C construct interacted
strongly with the p160 transcriptional coactivator TIF2 in a
DAC-dependent manner in the same assay (M. Liao, Y. A. Lefebvre,
and R. J. G. Haché, unpublished data).
By contrast, when the hinge region of GR was included with the LBD in
both GAL4-GR constructs (GR505C), a strong ligand-dependent activation of lacZ transcription reflecting the association
of the two GR peptides was observed. Similarly, the lacZ
gene was also strongly activated when the Gal activation domain-GR
DBD-hinge fusion protein (GalTA-GRX556) was
coexpressed with the Gal DBD-GR505C construct. Moreover, a
short GALTA-GR construct containing only amino acids 505 to
616 of GR also interacted strongly with
GALDBD-GR505C. Thus, these results exactly
mirrored the results of our in vitro assays in implicating the hinge
region of GR in receptor oligomerization of the GR in solution in vivo
The hinge region of GR is required for GR-GR binding in solution in
mammalian cells.
To assess whether the hinge region of GR
functioned to promote receptor oligomerization in mammalian cells prior
to its arrival on DNA, we examined GR-GR interactions in a nuclear
cotransport assay.
GR exchanges between a steroid-free, hsp-complexed cytoplasmic form and
a liganded hsp-free nuclear form. Transport of GR into the nucleus is
mediated by two nuclear localization sequences (NLSs), NL1 and NL2. NL2
occurs within the receptor LBD and mediates the partial transfer of GR
to the nucleus in many cell types including simian COS7 cells, while
NL1 is a short basic motif in the hinge region of GR that is sufficient
for complete nuclear transfer of the receptor in the same cell lines
(51). Mutations in NL1 dramatically impede the
translocation of the receptor to the nucleus upon exposure to ligand
(51). We hypothesized that if GR-GR binding could occur in
the cytoplasm prior to nuclear uptake, then coexpression of WT GR could
be expected to promote an increase in the transfer of NL1
GRs to the nucleus. This hypothesis was elegantly validated for PR
several years ago (23).
Therefore, we examined whether coexpression of WT GR could increase the
nuclear localization of full-length GR with an inactivating substitution of 3 amino acids in NL1 (GRNL1
) (51) and a second GR construct with a deletion in the
hinge region of GR from amino acids 511 to 539 (GR
511-539) including NL1, but that also would be
expected to disrupt the oligomerization of GR in solution.
Because NL1 occurs within the GR hinge, it was necessary to first
ensure that site-directed mutagenesis of NL1 did not also affect GR-GR
binding. Therefore we compared the binding of two mutated forms of GR,
GRNL1
and GR
511-539, to myGR
in our immunoprecipitation binding assay (Fig.
6). Steroid-treated GRNL1
was retained on the myGR beads with the same efficiency as the WT receptor was (lanes 4 and 5). By contrast, GR
511-539 in dex-treated cells was unable to bind myGR (lane 6). Thus, NL1 did not appear to overlap significantly with determinants within the receptor hinge required for solution
dimerization of GR in vitro.

View larger version (67K):
[in this window]
[in a new window]
|
FIG. 6.
Binding of in vitro-translated 35S-labeled
GR to myGR immunoprecipitated from whole-cell extracts requires amino
acids 511 to 539. Immunoprecipitates from whole-cell extracts prepared
from Sf7 cells expressing myGR [Sf7 (GR+); lanes 4 to 6]
or control cells (Sf7, lanes 7 to 9) as indicated were tested for
binding to the in vitro-translated GRs, whose composition is
illustrated schematically at the top. All samples were treated with
10 6 M Dex. GR binding is compared to 10% of the input
from the in vitro translations shown in lanes 1 to 3.
|
|
Cotransport of GRNL1
and
GR
511-539 into the nucleus by WT GR was examined in the
experiment in Fig. 7.
GR expression was accomplished by
transient transfection, and localization was monitored by indirect
immunofluorescence. For this experiment, a c-myc epitope tag was
introduced onto the N terminus of the two mutant GRs
(myGRNL1
and myGR
511-539)
but tag was absent from the WT receptor. In this configuration,
the myc tag antibody 9E10 could be used to show the subcellular
localization of the mutant GRs in the presence of the WT receptor.
Second, Western blotting was used to ensure that the ratio of WT GR to
mutated receptor was at least 4:1 in all experiments (Fig. 7A). This
ratio enhanced the opportunity for dimerization of the mutated
receptors with WT GR while ensuring that differences in subcellular
localization between different constructs did not arise due to
differences in the relative amounts of the GRs expressed. The
WT/mutated GR ratio was obtained by decreasing the amount of mutated
receptor plasmids expressed rather than overexpressing the WT GR.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 7.
Amino acids 511 to 539 are required for oligomerization
of GR in mammalian cells in vivo. Physical interaction between GRs in
transiently transfected COS7 cell was assessed by the ability of WT GR
to promote the nuclear localization of myGR derivatives lacking the
major GR NLS, NL1. (A) Western analysis of whole-cell extracts prepared
from COS7 cells expressing WT GR and myGR derivatives singly (lanes 1 to 3) and in combination (lanes 4 and 5) with the common buGR antibody
illustrating the minimum 4:1 ratio of expression for WT GR to myGR
derivatives used in the immunofluorescence assays in panel B. A summary
of the composition of the constructs employed in this experiment is given at the top. (B) In situ
immunofluorescence analysis of the localization of WT GR using antibody
buGR (GR WT) and of the myGR derivatives using anti-myc antibody 9E10
(remaining panels) before Dex treatment ( Dex) and following a 1-h
treatment with 10 6 M Dex (+ Dex). Photomicrographs of the
immunofluorescence pattern of representative cells are shown to the
left, while quantification of observations of a minimum of 150 cells
for each sample in each of a minimum of three independent experiments
performed in triplicate are shown to the right. As described previously
(48), GR localization in each cell was categorized as
completely or mostly nuclear (solid grey bars), equally distributed
throughout the cell (stippled bars), or localized predominantly or
exclusively to the cytoplasm (white bars). The error bars indicate the
standard errors of the means. Bar, 10 µm.
|
|
Prior to steroid treatment, WT GR and the mutated receptors were
localized almost completely to the cytoplasm (Fig. 7B). Dex treatment
of COS7 cells results in the rapid and complete transfer of WT GR to
the nucleus. By contrast, both myGRNL1
and
myGR
511-539 become only partially nuclear. Previously, we demonstrated that the localization and subcellular trafficking of GR
in transiently transfected cells can be accurately monitored by manual
scoring of GR localization in hundreds of transfected cells (24,
48, 51). The results accurately reflect the average behavior of
GR in the cells. In these experiments, the GR in the transfected cells
has been classified according to three categories, mostly or completely
nuclear, equally distributed within the cell, and predominantly or
exclusively cytoplasmic. Thus, following hormone treatment, WT GR was
concentrated in the nucleus of virtually all cells while
myGRNL1
and myGR
511-539 were
equally distributed between the nucleus and cytoplasm in over 60% of
the cells scored. Further, biochemical fractionation experiments
indicated that myGRNL1
and
myGR
511-539 associated similarly with chromatin (Savory
et al., unpublished).
Coexpression of WT GR with myGRNL1
(GRWT + myGRNL1
) resulted in
a sizable increase in the transfer of myGRNL1
to the nucleus following Dex treatment, such that
myGRNL1
became concentrated in the nucleus of
80% of the cells scored. By contrast, the localization of
myGR
511-539 was completely unaffected by coexpression of the WT GR (compare myGR
511-539 with GR + myGR
511-539). These results are completely consistent
with the results in vitro and in yeast and provide strong evidence that
liganded GR is able to oligomerize in the cytoplasm of the mammalian
cell in a manner that requires the receptor hinge region.
Since GR within the nucleus is targeted to DNA, it was possible that
the increased nuclear localization of myGRNL1
reflected an increase in the DNA occupancy of this receptor in the
nucleus that might serve to anchor the protein and decrease its rate of
nuclear export, rather than directly through increased nuclear import
through piggy-backing with the WT GR. To distinguish between these
possibilities, we directly examined the effect of GR DNA binding in the
cotransport assay (Fig. 8).
In the first instance, a full-length
GR containing a point mutation in the DBD that abrogates DNA binding by
the receptor (GFP-GRR496H) remained competent to promote
the nuclear accumulation of the full-length myGRNL1
clone. In the second instance, GR
truncated from the N terminus through the DBD to amino acid 505 (buGR505C) was similarly able to promote an increase in the
nuclear localization of the NL1
version of the same
peptide (myGR505CNL1
). Thus, we conclude that
the increased transfer of NL1
GRs to the nucleus that was
dependent on amino acids 511 to 539 of GR occurs independently from the
binding of GR to DNA and reflects the cotransport of GR oligomers into
the nucleus.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 8.
Solution oligomerization of GR in mammalian cells is
independent of the targeting of GR to DNA. (A) The new constructs
(GFP-GRR496H, buGR505C, and
myGR505CNl1 ) used in this experiment are
summarized schematically. A schema of the
myGRNL1 construct is shown in Fig 7. (B) In
situ immunofluorescence analysis of the localization of
GFP-GRR496H, myGRNL1 ,
buGR505C, and myGR505CNL1
expressed singly and in the combinations shown. Dex treatment at
10 6 M for 1 h was performed as indicated. Specific
localization of the GR constructs was visualized as follows:
GFP-GRR496H using direct fluorescence;
myGRNL1 by indirect immunofluorescence
analysis using antibody 9E10 followed by a rhodamine-red-conjugated
anti-mouse secondary antibody (allowing the detection of
myGRNL1 in the presence of
GFP-GRR496H); buGR505C by indirect
immunofluorescence using antibody BuGR2 and a
fluorescein-conju- gated anti-mouse secondary antibody;
myGR505CNL1 by indirect immunofluorescence
using antibody 9E10 followed by a fluorescein-conjugated anti-mouse
secondary antibody. Photomicrographs of the immunofluorescence pattern
of representative cells are shown to the left, while quantification of
observations of a minimum of 150 cells for each sample in each of a
minimum of three independent experiments performed in triplicate is
shown to the right. The localization of
myGRNL1 prior to steroid treatment is shown
in Fig. 7 and is not repeated here. GR localization in each cell was
categorized as completely or mostly nuclear (solid grey bars), equally
distributed throughout the cell (stippled bars), or localized
predominantly or exclusively to the cytoplasm (white bars). The error
bars indicate the standard errors of the means. Bar, 10 µm.
|
|
Cotransport of GR into the nucleus by MR demonstrates a heteromeric
interaction between GR and MR that is mediated through the GR LBD.
A central issue in corticosteroid hormone action is the potential for
interaction between GR and MR following corticosteroid treatment.
Recent work has suggested that GR and MR can converge on palindromic
DNA response elements to form receptor heterodimers (37,
60). However, such effects could be precluded by
homodimerization of GR in solution unless GR and MR also had a similar
ability to form heterodimers. Therefore, to begin to investigate
whether GR might also interact in solution with MR, we examined whether MR could substitute for GR in promoting the nuclear transfer of the
NL1-deficient myGR constructs (Fig. 9).

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 9.
MR promotes the nuclear uptake of GR irrespective of GR
amino acids 511 to 539. (A). Western blot of COS7 cell extracts
comparing the levels of the MR and GR constructs in panel B, using the
antibody BuGR. A schematic of the buMR construct is shown at the top of
the panel. The GR constructs used are summarized in Fig. 7. (B) In situ
immunofluorescence analysis of GR and MR peptide localization in
transfected COS7 cells prior to Dex treatment ( Dex) or following 1 h
treatment with 10 6 M Dex ( Dex). The localization of
the GR constructs prior to hormone treatment is shown in Fig. 7 and is
not repeated here. Antibody buGR was used to identify the localization
of buMR, while myc epitope antibody 9E10 was used to localize the myGR
derivatives in both the absence and presence of buMR. Photomicrographs
of the immunofluorescence pattern of representative cells are shown to
the left, while quantification of our observations, performed as
described in the legend to Fig. 7 is displayed to the right. MR-GR
localization in each cell was categorized as completely or mostly
nuclear (solid grey bars), equally distributed throughout the cell
(stippled bars), or localized predominantly or exclusively to the
cytoplasm (white bars). Bar, 10 µm.
|
|
First, to monitor the ratio of MR to GR expressed in cotransfections,
we introduced an epitope tag for the GR antibody buGR into MR. We then
titrated the relative levels of MR upon coexpression with
myGRNL1
and myGR
511-539 to
the minimum 4:1 ratio used with WT GR (Fig. 9A).
Prior to steroid treatment, MR expressed by transient transfection was
distributed mostly equally in the cell. Dex, which binds MR and has
agonist activity at 10
6 M (25), induced the
rapid and complete transfer of MR to the nucleus, while the
myGRNL1
and myGR
511-539 constructs were distributed mostly equally throughout the cells, as
before (Fig. 9B).
MR substituted very efficiently for WT GR in the cotransport experiment
with myGRNL1
, promoting the predominant nuclear occupancy of myGRNL1
in close to 80% of the cells scored (buMR + myGRNL1
).
Thus, GR also appears to oligomerize with MR in the cytoplasm. However, by contrast to GR, buMR was equally efficient in promoting the nuclear
accumulation of myGR
511-539 (buMR + myGR
511-539). Exactly the same result was obtained when
the cells were treated with the natural corticosteroid cortisol (Savory
et al., unpublished).
Since this result suggested that heteromeric interaction between GR and
MR occurred through a surface on GR distinct from that required for
GR-GR binding, we began to delimit this difference by comparing the
ability of WT GR and buMR to promote the nuclear occupancy of two
additional GR constructs (Fig. 10A).
The first construct (GFP-GRN524
NL1
) contained the N terminus of GR to amino acid
524, included the site-directed elimination of NL1, and contained an
N-terminal GFP tag to allow direct visualization of the protein in the
cell. The second construct contained the GR LBD from amino acids 540 to
795 with sequential N-terminal myc and buGR tags
(myGR540C). Titrations were again performed to ensure the
minimum 4:1 ratio between WT GR, buMR, and the mutated GR constructs
(52). As predicted from the absence of both GR NLSs,
GFP-GRN524 NL1
was exclusively localized to
the cytoplasm in almost all cells while the NL2-containing myGR540C was partially nuclear (Fig. 10B). Addition of WT
GR to cells expressing GFP-GRN524 NL1
promoted a strong shift in the distribution of GFP-GRN524
NL1
toward the nucleus (GR + GFP-GRN524
NL1
) but had no effect on the distribution of the
GR LBD (GR+myGR540C). By contrast, the effect of
coexpression of MR was exactly reversed. Coexpression of buMR strongly
enhanced the nuclear import of myGR540C (buMR+NL1
myGR540C), but had no
effect on the localization of GFPGRN524 NL
(buMR + GFP-GRN524 NL1
).

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 10.
MR-dependent nuclear uptake of GR is mediated through
the GR LBD. In situ immunofluorescence analysis of the ability of
full-length GR and MR (buMR) to influence the subcellular localization
of GFP-GRN524NL1 and myGR540C
(summarized schematically at the top) in COS7 cells is shown. Cells
examined in the absence of Dex treatment are indicated ( Dex), while
all other samples were examined following a 1-h treatment with
10 6 M Dex ( Dex). The receptor combinations expressed
are as indicated in the middle of each data set. The localization of
GRWT and buMRWT prior to hormone treatment was
shown previously and is not repeated here. Localization of
GFPGRN524 NL1 was determined by observation
of direct fluorescence from fixed cells, while localization of GR
and buMR was done by indirect immunofluorescence using antibody
buGR2 and localization of myGR540C was done by
indirect immunofluorescence using antibody 9E10. Quantification of our
observations, performed as described in the legend to Fig. 7, is
displayed to the right, while representative photomicrographs are shown
to the left. MR-GR localization in each cell was categorized as
completely or mostly nuclear (solid gray bars), equally distributed
throughout the cell (stippled bars), or localized predominantly or
exclusively to the cytoplasm (white bars). Bar, 10 µm.
|
|
This striking contrast in the interaction of these GR peptides with WT
GR and WT MR substantiates the likelihood that GR oligomerization and
heteromeric interactions between GR and MR originate in the cytoplasm
of the cell through distinct interfaces in the hinge region and LBD of
GR, respectively.
 |
DISCUSSION |
How, where, and with what nuclear hormone receptors partner in the
cell can predetermine their ability to regulate gene expression prior
to their arrival on DNA (39, 40). In this work, we have demonstrated the potential for corticosteroid receptor multimers to
form in solution in the cytoplasm and to be maintained through the
transport of these receptors into the nucleus. Oligomerization of GR in
solution required determinants within a short region of the receptor
hinge distinct from the DNA-dependent dimerization interface in the
receptor DBD. By contrast, a separate interaction with MR appeared to
be dependent solely on the GR LBD. These results suggest that
corticosteroid signaling may involve an interplay between GR and MR
that is more complex than has previously been appreciated.
Evidence has been presented supporting the DNA-independent
oligomerization of GR in mammalian tissue culture cells and in yeast
through an interface within the receptor hinge region.
Immunoprecipitation binding experiments, GST pulldown assays, and
direct-binding experiments have shown that a short region of the GR
hinge is necessary and sufficient for GR-GR binding and is likely to be
involved in direct protein-protein contacts between receptor monomers.
It seems most likely that the GR-GR interaction reflects simple
dimerization of the receptor. In particular, this appears to be
supported by the results of the peptide cross-linking experiments.
However, at present we cannot exclude the potential formation of
higher-order complexes of GR. Indeed, the RXR nuclear receptor has been
shown previously to form a tetrameric complex prior to ligand binding (7, 21).
Our results provide the first indication of a requirement for amino
acids within the hinge region of a nuclear receptor for oligomerization
and sets the determinants for solution oligomerization of GR apart from
those required for the dimerization of the other steroid and nuclear
hormone receptors. Only PR exhibits limited similarity to GR in
solution dimerization, in that its hinge region has been proposed to
stabilize dimerization of PR mediated through the receptor LBD
(59, 66).
Although our results demonstrate a requirement for the GR hinge in
solution dimerization of GR, they do not exclude the potential for
additional protein-protein contacts to occur between monomers that
could further stabilize the interaction and be important to signaling
downstream from GR. Indeed, the minimum region of GR that appears to be
required for GR-GR binding in solution, amino acids 505 to 524, may
reflect a central core requirement rather than a complete
oligomerization domain. While a direct interaction was demonstrated in
vitro with high concentrations of the peptide from amino acids 505 to
550, all of the interactions detected in vivo were with GR peptides
that included at least portions of the receptor LBD or DBD in addition
to the minimal domain. A more complete description of the nature of the
complete surface mediating GR oliogmerization in solution awaits a
mutagenic survey or direct structural analysis.
The possibility of additional intramolecular contacts outside of the
minimal core domain of GR would be consistent with observations that
have been made for the PR, ER, and AR receptors (30, 32, 58,
59). For GR, the potential for additional communication between
receptor domains has been demonstrated in several studies. For example,
Lefstin et al. have established that the receptor LBD communicates
directly with the DBD (34), while the synergistic nature
of the AF-1 and AF-2 transcriptional activation functions within GR
suggests communication between the receptor N terminus and LBD
(26).
Like other nuclear hormone receptors, GR is a shuttling protein that
traffics continuously between the nucleus and cytoplasm (13). Further, NL1
GRs redistribute rapidly
to the cytoplasm (50). Thus, our cotransport experiments
present a strong argument that GR oligomers form in the cytoplasm and
are transported together into the nucleus and that the
NL1
derivatives of GR accumulate further through a
continuous facilitation of their transport into the nucleus. Indeed,
cotransport efficiency was maintained between GR peptides containing
only the receptor hinge and LBDs. The ability to form receptor dimers
prior to the arrival on DNA could be expected to have several
advantages for GR, including an increased ability to recognize and bind
cognate DNA sequences within chromatin and the potential for more
efficient interaction with transcriptional coregulatory molecules.
We find it intriguing and potentially highly significant that the
solution dimerization domain of GR overlaps closely with its basic NL1
nuclear import signal. These results suggest that a close juxatposition
of the basic NL1 NLSs within the GR dimer might play a significant role
in promoting the transport of GR into the nucleus. The GR NL1 contains
a core basic motif typical of NLSs that are targeted to the nucleus by
importin
proteins (50, 57). This central core motif is
required for the binding of GR to importin
in vitro and in
two-hybrid experiments and is required for NL1 function
(50).
Importin
proteins bind to basic nuclear import sequences through a
series of armadilio (arm) repeats within a large central domain of the
proteins (9). Specificity for binding is found within
individual arm repeats, and each importin
has the potential to bind
at least two basic motifs (8). Thus, dimerization of GR in
a manner that would closely juxtapose the basic NL1 motifs could
increase the attraction of the receptor for importin
. Alternatively, a closely spaced interaction with multiple importin
proteins could facilitate transport by increasing interactions with
importin
.
In additional experiments that are being prepared separately for
publication (T. Antakly et al., unpublished data), immunogold electron
microscopy has been used to detect the intracellular localization of GR
in rat liver cells. The results of these experiments confirm the
presence of GR dimers in the cytoplasm and nucleus. Intriguingly,
however, GRs associated with the nuclear pore were predominantly
detected as higher-order multimers, mostly containing four molecules of
GR. These results suggest that the juxaposition of basic NLSs within
the GR dimer, as well as the potential convergence of importin
proteins at importin
, may reflect the predominant mechanism for the
transport of GR into the nucleus.
However, oligomerization of GR would not seem to be required for
NL1-mediated nuclear transport, since hsp-associated GR monomers are
transferred to the nucleus (41, 49) in an NL1-dependent manner (50). Nonetheless, in our experiments it remains
possible that at least some of the decreased nuclear occupancy observed for the cotransported NL1
GRs (80% nuclear) compared to
the WT receptor (98% nuclear) reflects transport efficiency of
receptor dimer, in addition to being a reflection of the efficiency or
stability of dimerization.
Evidence obtained for the heterodimerization of MR and GR provides an
additional new level of support for the coordinate action of these
receptors in regulating transcription. Previous transient transfection
assays have shown that full length MR and GR could cooperate to
activate transcription as DNA-bound heterodimers (37, 60).
However, solution dimerization of GR in the absence of heteromeric
interactions with MR, would have been expected to significantly limit
the potential of DNA-bound GR-MR heterodimers to form.
By contrast, the separation of the surfaces required for
homodimerization of GR and heterodimerization of GR with MR suggests exciting new possibilities for functional cooperation between corticorticosteroid receptors. In particular, our results suggest the
potential for the formation of higher-order GR-MR regulatory complexes
consisting of two molecules of GR for each molecule or more of MR. This
possibility is supported by the observation that MR promoted the
cotransport of NL1
GR, which formed homodimers, as
efficiently as it promoted the nuclear transfer of GR540C,
which did not. Establishing whether MR is also able to homodimerize in
solution and how this interaction influences its interactions with GR
becomes an obvious objective. How these DNA-independent interactions
are affected by binding to hormone response elements also remains to be determined.
Finally, experiments examining the overlap in localization between GR
and MR in the nucleus of hippocampal neurons (64) introduces the possibility that association of GR and MR in solution may be subject to regulation. If GR and MR form heterodimers in solution and GR-MR heterodimers target DNA indistinguishably from homodimers, it would be expected that stimulation of hippocampal neurons with corticosteroid concentrations high enough to activate both
receptors would result in a complete overlap in the localization of the
two receptors in the nucleus. However, one careful study of the
localization of GR and MR in hippocampal neurons revealed only a
partial overlap in the localization of GR and MR to discrete clusters
within the nucleus (64). These results suggest that heterodimerization of GR with MR is not completely permissive but is
subject to additional constraints in the cell whose nature remains to
be revealed.
 |
ACKNOWLEDGMENTS |
We are grateful to K. Yamamoto and M. Petkovitch for providing
plasmids used in this study. We also thank our colleagues in the
Haché and Lefebvre laboratories for their helpful comments and assistance.
This work was supported from an operating grant from the Medical
Research Council of Canada to Y. A. Lefebvre. R. J. G. Haché is a Scientist of the Medical Research Council of Canada,
while G. G. Préfontaine holds an MRC Studentship.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: The Loeb Health
Research Institute at the Ottawa Hospital, 725 Parkdale Ave., Ottawa, Ontario, Canada K1Y 4E9. Phone: (613) 761-5142. Fax: (613) 761-5036. E-mail: ylefebvre{at}ottawahospital.on.ca.
 |
REFERENCES |
| 1.
|
Beato, M.,
P. Herrlich, and G. Schütz.
1995.
Steroid hormone receptors: many actors in search of a plot.
Cell
83:851-857[CrossRef][Medline].
|
| 2.
|
Benediktsson, R., and C. R. Edwards.
1996.
11-beta-hydroxysteroid dehydrogenases: tissue-specific dictators of glucocorticoid action.
Essays Biochem.
31:23-36[Medline].
|
| 3.
|
Boruk, M.,
J. G. Savory, and R. J. Haché.
1998.
AF-2-dependent potentiation of CCAAT enhancer binding protein beta-mediated transcriptional activation by glucocorticoid receptor.
Mol. Endocrinol.
12:1749-1763[Abstract/Free Full Text].
|
| 4.
|
Bourguet, W.,
M. Ruff,
P. Chambon,
H. Gronemeyer, and D. Moras.
1995.
Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha.
Nature
375:377-382[CrossRef][Medline].
|
| 5.
|
Brzozowski, A. M.,
A. C. Pike,
Z. Dauter,
R. E. Hubbard,
T. Bonn,
O. Engstrom,
L. Ohman,
G. L. Greene,
J. Å. Gustafsson, and M. Carlquist.
1997.
Molecular basis of agonism and antagonism in the oestrogen receptor.
Nature
389:753-758[CrossRef][Medline].
|
| 6.
|
Chen, S.,
J. Wang,
G. Yu,
W. Liu, and D. Pearce.
1997.
Androgen and glucocorticoid receptor heterodimer formation. A possible mechanism for mutual inhibition of transcriptional activity.
J. Biol. Chem.
272:14087-14092[Abstract/Free Full Text].
|
| 7.
|
Chen, Z.,
J. Iyer,
W. Bourguet,
P. Held,
C. Mioskowski,
L. Lebeau,
N. Noy,
P. Chambon, and H. Gronemeyer.
1998.
Ligand- and DNA-induced dissociation of RXR tetramers.
J. Mol. Biol.
275:55-65[CrossRef][Medline].
|
| 8.
|
Conti, E.,
M. Uy,
L. Leighton,
G. Blobel, and J. Kuriyan.
1998.
Crystallographic analysis of the recognition of a nuclear localization signal by the nuclear import factor karyopherin alpha.
Cell
94:193-204[CrossRef][Medline].
|
| 9.
|
Cortes, P.,
Z. S. Ye, and D. Baltimore.
1994.
RAG-1 interacts with the repeated amino acid motif of the human homologue of the yeast protein SRP1.
Proc. Natl. Acad. Sci. USA
91:7633-7637[Abstract/Free Full Text].
|
| 10.
|
Dahlman-Wright, K.,
H. Siltala-Roos,
J. Carlstedt-Duke, and J. Å. Gustafsson.
1990.
Protein-protein interactions facilitate DNA binding by the glucocorticoid receptor DNA-binding domain.
J. Biol. Chem.
265:14030-14035[Abstract/Free Full Text].
|
| 11.
|
Dahlman-Wright, K.,
A. Wright,
J. Å. Gustafsson, and J. Carlstedt-Duke.
1991.
Interaction of the glucocorticoid receptor DNA-binding domain with DNA as a dimer is mediated by a short segment of five amino acids.
J. Biol. Chem.
266:3107-3112[Abstract/Free Full Text].
|
| 12.
|
Dahlman-Wright, K.,
A. P. Wright, and J. Å. Gustafsson.
1992.
Determinants of high-affinity DNA binding by the glucocorticoid receptor: evaluation of receptor domains outside the DNA-binding domain.
Biochemistry
31:9040-9044[CrossRef][Medline].
|
| 13.
|
Defranco, D. B.,
A. P. Madan,
Y. Tang,
U. R. Chandran,
N. Xiao, and J. Yang.
1995.
Nucleocytoplasmic shuttling of steroid receptors.
Vitam. Horm.
51:315-338[Medline].
|
| 14.
|
De Kloet, E. R.,
E. Vreugdenhil,
M. S. Oitzl, and M. Joels.
1998.
Brain corticosteroid receptor balance in health and disease.
Endocr. Rev.
19:269-301[Abstract/Free Full Text].
|
| 15.
|
DeMarzo, A. M.,
C. A. Beck,
S. A. Onate, and D. P. Edwards.
1991.
Dimerization of mammalian progesterone receptors occurs in the absence of DNA and is related to the release of the 90-kDa heat shock protein.
Proc. Natl. Acad. Sci. USA
88:72-76[Abstract/Free Full Text].
|
| 16.
|
Denis, M., and J. Å. Gustafsson.
1989.
Translation of glucocorticoid receptor mRNA in vitro yields a nonactivated protein.
J. Biol. Chem.
264:6005-6008[Abstract/Free Full Text].
|
| 17.
|
Drouin, J.,
Y. L. Sun,
S. Tremblay,
P. Lavender,
T. J. Schmidt,
A. de Lean, and M. Nemer.
1992.
Homodimer formation is rate-limiting for high affinity DNA binding by glucocorticoid receptor.
Mol. Endocrinol.
6:1299-1309[Abstract].
|
| 18.
|
Fawell, S. E.,
J. A. Lees,
R. White, and M. G. Parker.
1990.
Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor.
Cell
60:953-962[CrossRef][Medline].
|
| 19.
|
Freedman, L. P.,
S. K. Yoshinaga,
J. N. Vanderbilt, and K. R. Yamamoto.
1989.
In vitro transcription enhancement by purified derivatives of the glucocorticoid receptor.
Science
245:298-301[Abstract/Free Full Text].
|
| 20.
|
Funder, J. W.
1997.
Glucocorticoid and mineralocorticoid receptors: biology and clinical relevance.
Annu. Rev. Med.
48:231-240[CrossRef][Medline].
|
| 21.
|
Gampe, R. T., Jr.,
V. G. Montana,
M. H. Lambert,
G. B. Wisely,
M. V. Milburn, and H. E. Xu.
2000.
Structural basis for autorepression of retinoid X receptor by tetramer formation and the AF-2 helix.
Genes Dev.
14:2229-2241[Abstract/Free Full Text].
|
| 22.
|
Garabedian, M. J., and K. R. Yamamoto.
1992.
Genetic dissection of the signaling domain of a mammalian steroid receptor in yeast.
Mol. Biol. Cell.
3:1245-1257[Abstract].
|
| 23.
|
Guiochon-Mantel, A.,
H. Loosfelt,
P. Lescop,
S. Sar,
M. Atger,
M. Perrot-Applanat, and E. Milgrom.
1989.
Mechanisms of nuclear localization of the progesterone receptor: evidence for interaction between monomers.
Cell
57:1147-1154[CrossRef][Medline] |